Incomplete Intestinal Metaplasia Is Rare in Autoimmune Gastritis

Genta, Robert M.; Turner, Kevin; Robiou, Cristian; Singhal, Anuradha

doi:10.1159/000527479

Cited by 6 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…52 153 244 In the oxyntic compartment, the IM mainly exibits complete phenotype (see section 2.4.6). 245 Atrophic AIG (also referred as 'florid phase') commonly features hyperplastic polypoid lesions (rarely associated with pyloric gland adenomas) and either linear or nodular hyperplasia of the ECL cells (figure 9). 238 246 2.5.…”

Section: Commentmentioning

confidence: 99%

RE.GA.IN.: the Real-world Gastritis Initiative–updating the updates

Rugge,

Genta,

Malfertheiner

et al. 2024

Gut

Self Cite

View full text Add to dashboard Cite

At the end of the last century, a far-sighted ‘working party’ held in Sydney, Australia addressed the clinicopathological issues related to gastric inflammatory diseases. A few years later, an international conference held in Houston, Texas, USA critically updated the seminal Sydney classification. In line with these initiatives, Kyoto Global Consensus Report, flanked by the Maastricht-Florence conferences, added new clinical evidence to the gastritis clinicopathological puzzle.The most relevant topics related to the gastric inflammatory diseases have been addressed by the Real-world Gastritis Initiative (RE.GA.IN.), from disease definitions to the clinical diagnosis and prognosis. This paper reports the conclusions of the RE.GA.IN. consensus process, which culminated in Venice in November 2022 after more than 8 months of intense global scientific deliberations. A forum of gastritis scholars from five continents participated in the multidisciplinary RE.GA.IN. consensus. After lively debates on the most controversial aspects of the gastritis spectrum, the RE.GA.IN. Faculty amalgamated complementary knowledge to distil patient-centred, evidence-based statements to assist health professionals in their real-world clinical practice. The sections of this report focus on: the epidemiology of gastritis;Helicobacter pylorias dominant aetiology of environmental gastritis and as the most important determinant of the gastric oncogenetic field; the evolving knowledge on gastric autoimmunity; the clinicopathological relevance of gastric microbiota; the new diagnostic horizons of endoscopy; and the clinical priority of histologically reporting gastritis in terms of staging. The ultimate goal of RE.GA.IN. was and remains the promotion of further improvement in the clinical management of patients with gastritis.

show abstract

Section: Commentmentioning

confidence: 99%

RE.GA.IN.: the Real-world Gastritis Initiative–updating the updates

Rugge,

Genta,

Malfertheiner

et al. 2024

Gut

Self Cite

View full text Add to dashboard Cite

show abstract

“…27 Supporting this hypothesis is the fact that incomplete GIM is rarely found in autoimmune gastritis. 28,29 Rather complete subtypes are most common in autoimmune gastritis. 27,30 Autoimmune gastritis is more typically associated with neuroendocrine tumors, 22,31-33 a distinct pathway arising from enterochromaffin-like cell hyperplasia rather than GIM.…”

Section: Risk Of Cancer Progressionmentioning

confidence: 99%

The Risk of Gastric Intestinal Metaplasia and Implications for Management

Wang,

Jove,

Hwang

et al. 2024

Foregut: The Journal of the American Foregut Society

View full text Add to dashboard Cite

Gastric intestinal metaplasia (GIM) is a known precursor to gastric adenocarcinoma (GAC). Although the true prevalence of GIM is not known, it is estimated that around 5% of patients in the United States who undergo upper endoscopy with biopsies have GIM. Understanding the risk factors for progression to GAC is integral for management of this condition. In this review article, we discuss risk factors for progression to GAC and the implications for the management of patients with GIM.

show abstract